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for endometrial cancer
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Abstract
Background—The strongest known risk factor for endometrial cancer (EC) is obesity. To 
determine whether single nucleotide polymorphisms (SNPs) associated with increased body mass 
index (BMI) or waist-hip ratio (WHR) are associated with EC risk, independent of measured BMI, 
we investigated relationships between 77 BMI and 47 WHR SNPs and EC in 6,609 cases and 
37,926 country-matched controls.
Methods—Logistic regression analysis and fixed-effects meta-analysis were used to test for 
associations between EC risk and (i) individual BMI or WHR SNPs, (ii) a combined weighted 
genetic risk score (wGRS) for BMI or WHR. Causality of BMI for EC was assessed using 
Mendelian randomization, with BMIwGRS as instrumental variable.
Results—The BMIwGRS was significantly associated with EC risk (P=3.4×10−17). Scaling the 
effect of the BMIwGRS on EC risk by its effect on BMI, the EC odds ratio (OR) per 5kg/m2 of 
genetically predicted BMI was 2.06 (95% confidence interval(CI)=1.89–2.21), larger than the 
observed effect of BMI on EC risk (OR=1.55, 95%CI 1.44–1.68, per 5kg/m2). The association 
attenuated but remained significant after adjusting for BMI (OR=1.22, 95%CI=1.10–
1.39,P=5.3×10−4). There was evidence of directional pleiotropy (P=1.5×10−4). BMI SNP 
rs2075650 was associated with EC at study-wide significance (P<4.0×10−4), independent of BMI. 
EC was not significantly associated with individual WHR SNPs or the WHRwGRS.
Conclusions—BMI, but not WHR, is causally associated with EC risk, with evidence that some 
BMI-associated SNPs alter EC risk via mechanisms other than measurable BMI.
Impact—The causal association between BMI SNPs and EC has possible implications for EC 
risk modeling.
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Introduction
Endometrial cancer (EC: cancer of the lining of the uterine corpus) is the fourth most 
diagnosed cancer in European and North American women (1). Endometrial tumors are 
typically classified into two etiological types (2): hormonally driven Type 1, usually low 
grade endometrioid histology with ‘good’ prognosis (~80% of cases), and Type 2, non-
endometrioid, largely serous or clear cell histologies with poorer prognosis. Overall, the 
strongest known risk factor is obesity (3), with every 5kg/m2 increase in body mass index 
(BMI) increasing EC risk by up to 60% (4). Women with a BMI ≥30 kg/m2 have a ~3-fold 
overall increased EC risk compared to non-obese women (BMI <25), increasing to an 8-fold 
risk in women with BMI ≥40 (5). Obesity is most commonly associated with endometrioid 
EC, and may also modestly increase the risk of non-endometrioid tumors (3, 6). Body fat 
distribution, measured as waist-hip ratio (WHR) or waist circumference (WC), may 
influence EC risk but the evidence is weaker (4, 7). Additionally, whether the WHR/WC 
associations are independent of BMI remains to be clarified.
Association studies assessing cancer risk with variants proven to be associated with obesity 
may inform our understanding of the biological relationship between obesity and cancer 
risk, and also identify variants/genetic loci that play a direct role in the etiology of obesity-
associated cancers. Genome-wide association studies (GWAS) have now identified 97 loci 
associated with BMI and another 49 loci independently associated with WHR adjusted for 
BMI (8–11). Of these, a SNP in the FTO gene, in high linkage disequilibrium with obesity 
SNP rs1558902, is associated with a significantly increased risk of breast cancer (12), while 
combinations of BMI-associated variants summarised by a genetic risk score (GRS) have 
been associated with prostate and colorectal cancers (13, 14). A recent study of 3,376 
European-ancestry EC cases and 3,867 controls found an association between a 97-SNP 
BMI GRS and EC which disappeared after adjusting for BMI (15). However, a 26-SNP BMI 
GRS was found to be significantly associated with EC in Chinese cases and controls 
independently of measured BMI (16). The relationship between WHR-associated SNPs and 
EC is as yet unknown for any population.
We have investigated whether SNPs known to influence BMI (N=77) or WHR adjusted for 
BMI (N=47) in Europeans, are also associated with the risk of EC using a large sample of 
6,609 EC cases and 37,926 controls. We present the results of our association analyses for 
each SNP individually, and combined as a weighted genetic risk score (wGRS) (17) for each 
adiposity measure. Further, we investigated possibly pleiotropy of BMI risk SNPs using a 
Mendelian Randomization approach with a test for heterogeneity among the causal estimates 
from the different SNPs.
Material and Methods
Datasets
We analyzed four datasets from separate studies contributing to the Endometrial Cancer 
Association Consortium (ECAC), as detailed previously (18, 19), and as summarized in 
Supplementary Table 1). The first three comprised GWAS datasets genotyped using Illumina 
genotyping arrays, from Australia (“ANECS/QIMR/HCS”: 606 cases, 3,083 controls), and 
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the UK (“SEARCH/WTCCC”, 681 cases, 5,190 controls (18, 20)); “NSECG/CORGI”, 919 
cases, 894 controls(19, 21)). The fourth dataset (“iCOGS”) was genotyped using the 
‘iCOGs’ custom Illumina Infinium iSelect genotyping array comprising 211,155 SNPs 
chosen for follow-up and fine-mapping of hormonal cancer GWAS hits, and included 4,402 
cases recruited from 11 separate studies from 7 countries, and 28,758 controls from the same 
countries.
BMI information was available for subsets of cases and controls from the ANECS, 
SEARCH and iCOGS datasets (Table 1, Supplementary Table 2). Analyses that did not 
include BMI as a covariate included 6,609 cases and 37,296 controls; analyses including 
BMI as a covariate included 4,088 cases and 15,986 controls. The association between BMI 
and EC risk was assessed by meta-analysis of the ANECS, SEARCH and iCOGS datasets. 
There was modest evidence for heterogeneity (Ptrend All cases I2=73.4, P=0.02), driven by a 
lower estimate for the SEARCH dataset, with little difference between a fixed effects and 
random effects model (presented in Table 1).
WHR information was available only for a subset of WTCCC controls (the 1958 Birth 
Cohort, N=1259); the association between WHR wGRS and WHR was confirmed in this 
subset of individuals. Analyses assessing the association between WHR wGRS and EC risk 
included all cases and controls.
BMI and WHR SNP genotype imputation
Our analyses included 77 SNPs recently validated as associated with BMI at a genome-wide 
level of significance (P<5.0×10−8) in a large-scale meta-analysis including 339,224 
individuals of European ancestry from 125 separate studies conducted by the Genetic 
Investigation of Anthropomorphic Traits (GIANT) consortium (8, 9). Only SNPs significant 
in the primary analysis were included (i.e. we did not include SNPs significant only in 
secondary or conditional analyses, or in the analysis including other ancestries). Using the 
same criteria, we included 47 SNPs associated with WHR after adjustment for BMI 
(WHRadjBMI) in a GIANT meta-analysis including 210,088 individuals from 101 studies 
(10, 11); 34 of these WHR SNPs had also reached genome-wide significance in analyses 
including only women (11). The BMI and WHR SNPs were non-overlapping. SNPs that 
were not directly genotyped on either the Illumina or iCOGS platforms were imputed to the 
1000 Genomes dataset v3 (April 2012 release) using IMPUTE v2 (22) as described in (19). 
All target SNPs had imputation information scores >0.85 across datasets and minor allele 
frequencies >0.05.
Association of EC with individual BMI or WHR SNPs
The four datasets were analysed separately using unconditional logistic regression with a 
per-allele (1 degree of freedom) model using SNPTEST v2 (23), adjusting for principal 
components of the genomic kinship matrix as described previously (18, 19). The GWAS 
datasets were each analysed as a single stratum, the iCOGS dataset was adjusted for eight 
strata (six defined by country, while the large UK dataset was divided into ‘SEARCH’ and 
‘NSECG’). Given no indication for heterogeneity between studies, betas and their standard 
errors for each dataset were combined using standard fixed-effects meta-analyses across 
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studies in METAL (24). All statistical tests were 2-sided. P-values <4.0×10−4 (where 
P=0.05/124) were considered significant.
Association of EC with genetic risk scores for BMI and WHR
We next tested for associations between EC and the wGRS for BMI and WHR. For each 
individual in the study, the number of trait-increasing alleles at each SNP (between 0 and 2) 
was weighted by the reported effect size in the GIANT consortium meta-analysis (per-allele 
regression coefficient) on the relevant phenotype and then summed across SNPs 
(Supplementary Text) (8–11). As most WHR-associated SNPs showed a significant 
difference in effect between the sexes, we calculated the WHRwGRS using the effect size as 
reported for women (11). The weighted contributions from all SNPs were summed to give a 
BMIwGRS and two different WHRwGRS for each individual (a 34-SNP WHRwGRS 
including only SNPs reaching genome-wide significance in women, and a 47 SNP 
WHRwGRS including all WHR-associated SNPs for which we had data).
Associations between the BMIwGRS and BMI and the WHRwGRS and WHR were 
determined by linear regression, and associations between the BMIwGRS, WHRwGRS and 
case-control status by logistic regression. These analyses were performed separately for each 
study, and results combined using random effects meta-analysis. Associations between each 
wGRS and EC were performed per GRS unit (continuous) and after stratifying into quartiles 
based on the distribution in controls. All wGRS analyses were performed using the R 
software package (http://www.r-project.org/) with two-sided P-values <0.05 considered 
significant.
Finally, we used Mendelian Randomization (MR), with BMIwGRS as the instrumental 
variable, to assess the causality of BMI for EC. We genetically predicted the effect of a 
5kg/m2 increase in BMI on EC risk by scaling the natural logarithm of the OR of EC per 
unit increase in the BMIwGRS on BMI. Using the MR approach, if BMI is causal for EC 
then the observed BMI OR for EC should be consistent with that predicted using the scaled 
BMIwGRS. A larger observed than predicted OR would suggest that at least part of the 
observed BMI-EC association is attributable to bias or confounding inflating the observed 
estimates. Conversely, a larger predicted than observed OR might indicate pleiotropy or bias 
or confounding that has reduced the observed estimate towards the null. To formally test the 
MR assumption of no pleiotropy, we used the MR adaptation of Egger’s test – a method 
originally developed for assessing small-study bias in meta-analysis (25). In this setting each 
point on the funnel plot represents the causal estimate derived from one BMI SNP, and we 
are testing whether the causal estimates from weaker SNPs (those less strongly associated 
with BMI) are skewed towards either high or low values, compared with stronger variants. 
We used Cochran’s Q-test as a further test for heterogeneity in the causal estimates of the 
individual SNPs (where the analysis is over the 77 SNPs rather than over multiple studies, as 
would be more usual in a meta-analysis context), and used the result of this test to guide 
whether the best estimate of the causal effect of BMI on EC is the combined estimate from 
the fixed-effects or from the random-effects inverse-variance weighted meta-analysis of the 
per-SNP causal estimates.
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Results
There was evidence of association between EC and one BMI-associated SNP at P<4.0×10−4; 
SNP rs2075650 located within TOMM40 on chromosome 19 (per allele OR=1.13, 95% CI 
1.05–1.21, P=2.4×10−4) (Supplementary Table 3). The signal was similar in the subset of 
samples with BMI information (OR=1.18, 95% CI 1.10–1.26; P=2.0×10−4), and remained 
significant after including BMI as a covariate (OR=1.16, 95% CI 1.07–1.24, P=3.7×10−4). 
For the individual SNPs, there was a very modest positive correlation between the published 
effect on BMI and the estimated effect on EC risk (Pearson R=0.26, P=0.02), which was 
attenuated when only samples with BMI information were included (Pearson R=0.19, 
P=0.09), and disappeared completely after conditioning on BMI (Pearson R=0.004, P=0.96) 
(Supplementary Figure 1).
There was also evidence for association with one WHR SNP, rs10842707 at the ITPR2-
SSPN locus on chromosome 12 (OR=1.09, 95% CI 1.05–1.13, P=3.7×10−4) (Supplementary 
Table 4), although this signal fell below our study-wide significance threshold after adjusting 
for BMI (OR=1.08, 95% CI 1.01–1.14, P=1.1×10−2; unadjusted OR for the subset with BMI 
information was 1.07, 95% CI 1.01–1.13, P=2.4×10−2). There was no obvious correlation 
between published effect sizes for WHR SNPs and EC risk (Pearson R=−0.19, P=0.09; 
Supplementary Figure 2).
As expected, self-reported BMI was highly significantly associated with EC risk overall, 
with an OR=1.55 (95% CI 1.44–1.68, per 5kg/m2, P=1.8×10−26) for every 5kg/m2 increase 
in BMI (Table 1): ORs were somewhat greater for endometrioid (OR=1.56, 95% CI 1.42–
1.72) HERE than non-endometrioid/mixed (OR=1.50, 95% CI 1.43–1.57) histologies. The 
association between BMI and the BMIwGRS was significant in both cases and controls 
(Supplementary Figure 3); overall each weighted allele (i.e. each unit increase in the 
BMIwGRS) was associated with a 4.83kg/m2 increase in BMI, 95% CI 4.33–5.32, 
P=1.2×10−81, indicating the suitability of this score as an instrumental variable for BMI in 
our dataset (F statistic on a pooled analysis adjusting for study 587.7).
The BMIwGRS was significantly associated with EC risk in the entire dataset, with a per 
weighted allele OR=2.11 (95% CI 1.94–2.28, P=3.4×10−17: Table 2). Scaling according to 
the magnitude of the effect of the score on BMI (β=4.83kg/m2), we find the EC OR per 
5kg/m2 of genetically predicted BMI to be 2.06 (95% CI 1.89–2.21) (Figure 1). This effect 
is apparently driven by an association with endometrioid disease (scaled OR=2.21, 95% CI 
2.03–2.38, P=6.6×10−12). The overall association was similar for the subset with BMI 
information (scaled OR=2.18, 95% CI 1.96–2.41, P=4.2×10−12), and attenuated but 
remained significant after including BMI as a covariate in the model (scaled OR=1.22, 95% 
CI 1.12–1.34, P=5.3×10−4).
According to the Ptest, there was no significant evidence of directional pleiotropy (P=0.53), 
despite some possible asymmetry in the funnel plot (Supplementary Figure 4). However, 
Cochran’s Q-test did show some significant heterogeneity in the causal estimates from the 
individual SNPs (P=1.5×10−4), hence the causal effect of BMI on EC would be more 
appropriately estimated from the inverse-variance weighted random effects meta-analysis of 
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the 77 BMI SNPs (P=1.8×10−9). Unfortunately, this effect estimate cannot be interpreted 
since the SNP-BMI regression coefficients presented by the GIANT consortium are for an 
inverse-normalised transformation of BMI, from which effects on the kg/m2 scale cannot be 
derived. Nevertheless, we note that the causal lnOR estimate from the random-effects 
analysis of individual SNPs is ~10% higher than that from the equivalent fixed-effects 
analysis (Supplementary Figure 4), thus we infer that the true causal effect of BMI on EC is 
slightly larger than our best estimate under the assumption of no directional pleiotropy i.e. 
OR >2.06 per 5kg/m2 as predicted in our dataset. This is somewhat larger than the observed 
OR=1.55 (95% CI 1.44–1.68) per 5kg/m2 of reported BMI in this dataset, and also larger 
than previously published estimates of the effect of reported BMI on EC in epidemiological 
studies (e.g. OR 1.54, 95% CI 1.47–1.61, per 5kg/m2 (4); OR=1.57, 95% CI 1.54–1.61, per 
5kg/m2 for “Type1” largely endometrioid EC (3)).
Both WHRwGRS were significantly associated with WHR in the WTCCC control group 
(34-SNP WHRwGRS β=0.05, 95% CI 0.02–0.08, P=2.2×10−3; 47-SNP WHRwGRS 
β=0.05, 95% CI 0.03–0.08, P=1.8×10−4). As expected, neither WHRwGRS was associated 
with BMI (P=>0.80). The results for the 34-SNP WHRwGRS were very similar to those 
from secondary analyses using all 47 WHR SNPs, neither of which were significantly 
associated with EC risk (OR=1.02, 95% CI 0.99–1.04, P=0.09 and OR=0.97, 95% CI 0.63–
1.31, P=0.86, respectively) (Table 3), or with risk stratified by histology (data not shown).
Discussion
In this study we assessed whether SNPs associated with increased BMI or WHR are also 
associated with increased EC risk, either individually or in combination, and whether these 
genetic associations are independent of BMI. While BMI is clearly recognized as a major 
risk factor for EC, the role of WHR, independent of BMI, is less clear. Most studies 
including WHR have reported evidence for an association with EC (4, 26–32) but only four 
presented analyses adjusting for BMI, suggesting the WHR-EC risk association was 
attenuated in Caucasians (29–31), but not in Asians (32).
Combined as a wGRS, the 77 BMI-associated SNPs were highly significantly associated 
with BMI, even though the BMIwGRS explained only ~1% of the variance in BMI in our 
sample (less than the estimated 2.7% of the variance in BMI explained by 97 BMI-
associated SNPs across ancestries in the discovery dataset (9)). The BMIwGRS was also 
significantly associated with EC, explaining ~0.1% of the variance in risk and confirming 
the causal nature of the association between BMI and EC. Indeed, the association between 
genetically-predicted BMI (based on the 77 SNP BMIwGRS) and EC risk was somewhat 
larger than that between observed BMI (i.e. that calculated from self-reported height and 
weight) and EC risk, and we identified significant heterogeneity in the per-SNP causal 
estimates, both of which suggest some modest degree of directional pleiotropy. Furthermore, 
the overall association signal attenuated but did not disappear when adjusting for BMI 
(OR=1.22 vs 2.06 per 5kg/m2 genetically predicted BMI), which also suggests that these 
SNPs mainly, but not entirely, operate to increase EC risk via BMI. In particular, we note 
that one BMI SNP, rs2075650, was found to be associated with EC risk independent of BMI 
in our dataset.
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Our result could also (or instead) suggest that the aspect of body composition most relevant 
for EC risk is only partially captured by BMI; although BMI is widely used as a convenient 
proxy measure for adiposity, it is by no means a perfect measure (33). One would expect that 
the SNPs identified to date in GWAS of BMI, at least on aggregate, are more strongly 
associated with adiposity than with its proxy, BMI. Hence the combined effect of the 77 
BMI SNPs might be a better predictor of risk due to adiposity than BMI self-reported at a 
single time point (which could be subject to regression dilution). The effect of BMI on EC 
risk has been reported to be attenuated among ever users of hormone replacement therapy 
(HRT), as compared to never users (34). Although we were unable to stratify our analyses 
according to HRT use, we are confident that the difference between the effects of observed 
and genetically-predicted BMI on EC risk seen in our study is not attributable to an 
interaction between BMI and HRT use, since both analyses were based on the same set of 
women, and so will necessarily have included the same proportions of current, previous and 
never HRT users. However, the discrepancy between the observed and predicted effects of 
BMI on EC could theoretically point to negative confounding between measured BMI and 
EC, via HRT use and some other factor (e.g. socioeconomic status) associated with both 
higher BMI and less frequent HRT use.
The evidence for modest pleiotropy for BMI SNPs and EC risk has been reported previously 
in a study of Chinese women. A study of 26 SNPs then reported as (nominally) associated 
with different measures of obesity in GWAS datasets (35) identified a GRS-EC association 
in Chinese women (16), which attenuated but remained significant after adjusting for BMI. 
Direct comparison to our findings is difficult, due to differences in SNP selection and 
overlap, and also because the relationship between BMI and percentage body fat differs 
among ethnic groups (36). However, the results from our European-ancestry study contrast 
with those from another recent analysis of 3,376 European-ancestry EC cases and 3,867 
controls from the E2C2 consortium (15); neither cases nor controls from the E2C2 analysis 
overlap with those presented here. While the E2C2 analysis also identified a significant 
association between a 97-SNP GRS and EC risk (P=0.002), this association ablated after 
adjustment for BMI (P=0.78). The differences in findings between the two European studies 
may possibly reflect the BMI profiles of the two studies; while the mean BMI of the controls 
did not differ between the two studies (P=0.11), the mean BMI of cases in the E2C2 study 
was greater than that for cases in our study (P=0.017, mean difference of 0.43kg/m2). 
However, the differences are more likely to reflect the increased power of our larger study to 
detect modest effects. This is particularly pertinent to the single SNP findings. Although 
BMI SNP rs2075650 was found to be significantly associated with EC risk independent of 
BMI in our dataset (per allele OR of 1.13, 95% CI=1.05–1.21), this same SNP was not 
significantly associated with EC risk in the E2C2 analysis (15) (ORBMI-adjusted= 1.00, 95% 
CI=0.90–1.10), although there was some overlap between the 95% CIs. We note also that we 
find no evidence in support of the E2C2 tentative finding of a protective effect on EC of the 
subset of five BMI-risk alleles at loci known to be involved in Monogenic Obesity 
Syndromes, with OR point estimates above unity observed for the four loci we investigated 
in our study (rs6567160, MC4R, OR 1.02 (0.98–1.06), P=0.3; rs11030104, BDNF, OR 1.05 
(1.01–1.09), P=0.05; rs10182181, POMC/ADCY3, OR 1.02 (0.98–1.06), P=0.4; 
Supplementary Table 3).
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We also, for the first time, used a genetic approach to assess the influence of body fat 
distribution on EC risk, an epidemiological association which is less clear than that of 
adiposity as measured by BMI. Combined as a wGRS, 34 SNPs reported as significantly 
associated with WHR in women (11) were not significantly associated with EC in our 
sample. We focused on the 34-SNP WHRwGRS due to the marked sexual dimorphism 
amongst WHR-associated loci (11), however, the results did not differ when 47 SNPs were 
included in the WHRwGRS. Together, the 49 SNPs now reported as associated with WHR 
explain ~2.4% of the variance in WHR in women (~1.4% in both sexes combined) (11). As 
this is similar to the proportion of variation in BMI explained by currently known BMI-
associated SNPs, it seems most likely that the lack of association between the WHRwGRS 
and EC is due to a true lack of association between WHR and EC, rather than the smaller 
number of SNPs included in the WHRwGRS, particularly as the WHR-EC association seen 
in epidemiological studies seems to be accounted for by BMI (4). Rather than WHR, waist 
circumference (WC) may be a more relevant measure of central adiposity, with evidence that 
the association between WC and EC is independent of BMI (4). However, analysis of the 
genetic association between WC and EC awaits the discovery of additional WC-associated 
SNPs, as only six have been reported to date (four in Caucasians), none of which reached 
genome-wide significance in women only (11).
In summary, our combined results from weighted genetic risk scores and Mendelian 
Randomization analysis provide a further line of evidence that increasing BMI has a direct 
effect on EC risk, and thus that interventions aimed at weight loss should reduce that risk 
(5). We also found that SNP alleles associated with increased BMI have an aggregate effect 
on EC risk that is over and above that predicted by their effects on BMI. This suggests a 
possible degree of pleiotropy in SNP functions, indicating that these SNPs, and potentially 
other BMI-associated SNPs yet to be discovered, would be more useful components in an 
EC risk prediction model than BMI itself. In contrast, our genetic findings indicate that 
WHR is not independently associated with EC risk. These findings support the value of 
genetic approaches to verify causal relationships between epidemiological risk factors and 
cancer risk.
Supplementary Material
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Figure 1. Observed and predicted risks of increasing BMI on endometrial cancer
The predicted effect of a 5kg/m2 increase in BMI on EC risk was estimated by scaling the 
effect of the per weighted allele increase in the BMIwGRS on BMI (4.83 kg/m2) by the 
effect of the per weighted allele increase in the BMIwGRS on EC (OR 2.11) in our dataset 
(exp[(4.83/5)*ln(2.11)]). The predicted effect (grey arrow) of a per 5kg/m2 increase in BMI 
on endometrial cancer risk (OR 2.06) is larger than that observed in our study (OR 1.55).
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Table 3
Association of the 34- and 47-SNP waist-hip ratio weighted genetic risk score (WHRwGRS) with endometrial 
cancer risk
34-SNP wGRS 47-SNP wGRS
WHRwGRS1
Quartiles
Odds Ratio (95% CI) P-value Odds Ratio (95% CI) P-value
Q1 Reference Reference
Q2 1.00 (0.96–1.03) 9.5×10−1 0.99 (0.96–1.02) 4.5×10–1
Q3 0.98 (0.96–0.01) 7.0×10–2 098 (0.94–0.01) 2.6×10–1
Q4 0.99 (0.97–0.01) 3.2×10–1 0.98 (0.95–0.01) 1.3×10–1
Per wGRS quartile
increase in EC risk
0.99 (0.99–1.00) 1.7×10–1 0.99 (0.99–1.00) 2.4×10–1
wGRS as a
continuous variable
1.02 (0.99–1.04) 9.0×10–2 0.97 (0.63–1.31) 8.6×10–1
1
Range 34 SNP WHRwGRS: Overall 0.53–1.52 (mean 0.98, SD 0.12); Cases 0.57–1.36 (mean 0.98, SD 0.12); Controls 0.53–1.52 (mean 0.98, SD 
0.12). Range 47 SNP WHRwGRS: Overall 0.67–1.76 (mean 1.21, SD 0.14): Cases 0.67–1.69 (mean 1.22, SD 0.14); Controls 0.68–1.76 (mean 
1.20, SD 0.14).
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